Acute myeloblastic leukemia with maturation
acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils (WHO, 2001)
Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia (AML).
Acute myeloid leukemia (AML) is a type of cancer affecting blood cells that eventually develop into non-lymphocyte white blood cells. The disease originates from the bone marrow, the soft inner portion of select bones where blood stem cells develop into either lymphocyte or in this particular condition, myeloid cells. This acute disease prevents bone marrow cells from properly maturing, thus causing an accumulation of immature myeloblast cells in the bone marrow.
Acute myeloid leukemia is more lethal than chronic myeloid leukemia, a disease that affects the same myeloid cells, but at a different pace. Many of the immature blast cells in acute myeloid leukemia have a higher loss of function and thus, a higher inability to carry out normal functions than those more developed immature myeloblast cells in chronic myeloid leukemia (O’Donnell et al. 2012). Acute in acute myeloid leukemia means that the amounts of blast cells are increasing at a very high rate. Myeloid refers to the type of white blood cells that are affected by the condition.
Acute myeloid leukemia is the most common acute leukemia that is affecting the adult population.
The public source identifies “Acute myeloblastic leukemia with maturation” as acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils (WHO, 2001). This brief keeps that definition visible, then builds a research path around Acute, myeloblastic and leukemia.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Acute myeloblastic leukemia with maturation”, the useful work is to connect “acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils (WHO, 2001)” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 12, 2025. The linked authority identifier is Q4677940. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2012.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Acute myeloblastic leukemia with maturation”, its source revision and the description used here.
- Expand the search: follow Acute myeloblastic leukemia with maturation primary sources, Acute myeloblastic leukemia with maturation archive and Acute research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Acute myeloblastic leukemia with maturation”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Acute myeloblastic leukemia with maturation” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.